Summary of Radiopharm Theranostics Conference Call Company Overview - **Company**: Radiopharm Theranostics (NasdaqCM:RADX) - **Industry**: Radiopharmaceuticals - **Focus**: Clinical-stage company developing targeted oncology therapies with multiple programs in human trials across solid tumors [1][2] Key Points and Arguments RAD101 Program - **Current Status**: RAD101 is in phase IIb, nearing completion with a second interim analysis reported [2] - **Interim Results**: 18 out of 20 patients (90%) showed positive results, indicating effective diagnosis for brain metastasis where MRI was insufficient [3][4] - **Recruitment**: 27 out of 30 patients have been recruited, with completion expected in 2-3 weeks [4] - **Future Plans**: A meeting with the FDA is planned for June to discuss phase III trial design [5] - **Market Need**: There are approximately 300,000 new patients in the U.S. annually needing such treatments [5] Other Pipeline Products - **RAD204**: Currently in phase I trial for PD-L1 positive patients, progressing well with no negative side effects reported [6][7] - **RAD202**: Targeting HER2 expressing tumors, also in phase I, with positive tumor uptake and safety profile [7][8] - **BetaBart**: A new trial targeting B7H3 has started, with strong preclinical data and a focus on various solid tumors [9][10] - **KLK3 Targeting**: A unique approach in prostate cancer treatment using Tb-161, differentiating from PSMA targeting [11][12] Competitive Position - **First-Mover Advantage**: Radiopharm is positioned as a leader in clinical development for several of its products, with a competitive edge over companies like Aktis and Novartis [10] - **Market Scarcity**: There are few public companies in the radiopharmaceutical space, particularly in Australia and the U.S., which may sustain momentum in the sector [16] Execution Risks - **Recruitment Challenges**: The oncology field is crowded, making patient recruitment for trials competitive [20] - **Trial Allocation**: Hospitals may prioritize other trials over Radiopharm's, necessitating strategic site selection [20] Financial and Market Insights - **Market Discrepancy**: There is a noted 20%-25% premium for Radiopharm's stock on Nasdaq compared to ASX, attributed to the company's limited size and market exposure [22][23] - **Future Catalysts**: Key upcoming milestones include phase II readout of RAD101 between May and June, and phase I readouts for RAD204 and RAD202 by the end of the year [24] Additional Important Information - **Clinical Updates**: The company aims to provide multiple clinical updates in the next 2-3 months, with a focus on areas lacking competition [13][14] - **Safety and Efficacy**: Initial cohorts for RAD204 and RAD202 have not shown clinical efficacy due to low dosing, but higher doses are expected to yield results [17][18] - **Strategic Focus**: The company plans to evaluate which products to prioritize based on emerging clinical data later in the year [19]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $406.8 million, an increase of 4% year-over-year, while full-year revenue was $1.546 billion, up 0.5% [20] - Adjusted EPS for Q4 was $1.67, an increase of 4.7%, while full-year adjusted EPS was $6.08, a decrease of 10% from the prior year [26][30] - Operating cash flow for Q4 totaled $90.2 million, down from $157.7 million in Q4 2024 [27] Business Line Data and Key Metrics Changes - Radiopharmaceutical oncology, primarily from PYLARIFY, generated Q4 revenue of $240.2 million, down 9.7% year-over-year, and full-year revenue of $989.1 million, down 6.5% [20] - Precision Diagnostics delivered Q4 revenue of $143.2 million, a 22% increase, driven by DEFINITY and Neuraceq, which contributed $31 million in Q4 [21][14] - Strategic partnerships and other revenue increased by 203.3% to $23.3 million, largely due to MK-6240 [22] Market Data and Key Metrics Changes - PYLARIFY's volume grew approximately 4% year-over-year, with pricing discipline contributing to performance despite competitive pressures [12] - Neuraceq is expected to grow triple digits in 2026, driven by increased demand for Alzheimer's imaging [14] - DEFINITY maintained over 80% market share, delivering over $85 million in Q4 [14] Company Strategy and Development Direction - The company is focusing on radiodiagnostics, with plans to maintain leadership in PSMA PET imaging and prepare for the launch of a new PSMA PET formulation in Q4 2026 [8][36] - The strategic intent includes optimizing the cost structure and prioritizing investments in innovative PET radiodiagnostics [10] - The company plans to pursue value-maximizing alternatives for its radiotherapeutic assets while focusing on diagnostic opportunities [11][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive meaningful performance gains and deliver sustainable revenue growth in the mid and long term [11][36] - The company anticipates several product approvals in 2026, with a focus on commercial execution and regulatory milestones [30] - Management highlighted the importance of maintaining operational excellence and customer relationships to support growth [13] Other Important Information - The company completed the divestiture of its legacy SPECT business on January 1, 2026, to focus on PET radiodiagnostics [8] - The effective tax rate for Q4 was 19%, with a full-year rate of 25.3% [25] - Cash and cash equivalents stood at $359.1 million, with $200 million remaining for share buybacks [28] Q&A Session Summary Question: What is the timing for the new PSMA PET imaging agent's coding and reimbursement? - Management anticipates securing HCPCS code and transitional pass-through status by October 1, 2026, with a regional rollout planned for Q4 2026 [41][42] Question: How does the POSLUMA versus PYLARIFY study impact market dynamics? - Management expressed concerns about the study design and stated that its results do not factor into the current forecast for PYLARIFY [46][48] Question: Can you elaborate on pricing and unit growth for PYLARIFY in Q4? - Management indicated that Q4 performance exceeded expectations, with both volume growth and favorable pricing contributing to results [52] Question: What are the plans for radiotherapeutic assets? - Management is reviewing therapeutic assets for value optimization and may consider tuck-in acquisitions for diagnostic opportunities [61][62] Question: What is the growth outlook for Neuraceq? - Management expects Neuraceq to achieve triple-digit growth in 2026, supported by expanded manufacturing and deeper penetration in existing accounts [14][66]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $406.8 million, an increase of 4% year-over-year, while full-year revenue was $1,541.6 million, up 0.5% from the previous year [20][21] - Adjusted GAAP fully diluted earnings per share for Q4 were $1.67, an increase of 4.7%, while for the full year, it was $6.08, a decrease of 10% [26][30] - Gross profit margin for Q4 was 65.1%, down 289 basis points from Q4 2024, primarily due to decreases in PYLARIFY net price [22] Business Line Data and Key Metrics Changes - Radiopharmaceutical oncology, solely comprised of PYLARIFY, generated Q4 revenue of $240.2 million, down 9.7% year-over-year, and full-year revenue of $989.1 million, down 6.5% [20][21] - Precision Diagnostics delivered Q4 revenue of $143.2 million, a 22% increase, driven by DEFINITY's sales of $85.3 million [21] - Neuraceq contributed $31 million in Q4 and $51.4 million since its acquisition in late July [21][14] Market Data and Key Metrics Changes - The market for PYLARIFY is expected to see a decline of 8%-10% year-over-year due to increased competition and pricing dynamics [30][45] - Neuraceq is projected to grow triple digits in 2026, driven by increased demand for Alzheimer's imaging [14][31] - DEFINITY is expected to grow in the low to mid-single digits in 2026 [31] Company Strategy and Development Direction - The company is focusing on radiodiagnostics, with plans to maintain leadership in PSMA PET imaging and prepare for the launch of a new PSMA PET formulation in Q4 2026 [8][10] - The strategic intent includes divesting the legacy SPECT business to prioritize innovative PET radiodiagnostics [8][11] - The company aims to optimize its cost structure and selectively pursue value-maximizing alternatives for radiotherapeutic assets [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive performance gains and deliver sustainable revenue growth in the mid and long term [11][36] - The focus for 2026 will be on commercial execution and regulatory milestones, with expectations for several product approvals [11][30] - Management acknowledged the importance of maintaining operational excellence and customer relationships to support growth [13][14] Other Important Information - The company repurchased $100 million of its own shares during Q4 2025, leaving $200 million of authorization for buybacks outstanding [28] - The effective tax rate for Q4 was 19%, with an expected increase to 26% in 2026 [25][32] Q&A Session Summary Question: What is the timing for the new PSMA PET imaging agent's coding and reimbursement? - Management anticipates securing HCPCS coding and transitional pass-through status by October 1st, with a commercial rollout planned for Q4 2026 [41][42] Question: How does the study comparing PYLARIFY and POSLUMA impact market dynamics? - Management expressed concerns about the study design and stated that the results do not factor into their forecast for PYLARIFY [46][48] Question: Can you elaborate on pricing and unit growth in Q4 2025? - Management reported a 4% volume growth for PYLARIFY in Q4, with expectations for low single-digit growth in 2026 [52][54] Question: What are the plans for radiotherapeutic assets? - Management is reviewing the therapeutic assets for value optimization and may consider tuck-in acquisitions for diagnostic opportunities [60][62] Question: What is the growth outlook for Neuraceq? - Management expects triple-digit growth for Neuraceq in 2026, driven by expanding manufacturing and market penetration [14][66]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $406.8 million, an increase of 4% year-over-year, while full-year revenue was $1,541.6 million, up 0.5% [21] - Gross profit margin for Q4 was 65.1%, down 289 basis points from Q4 2024, primarily due to decreases in PYLARIFY net price [23] - Operating profit for Q4 was $138.9 million, a decrease of 8.5%, with reported profit for Q4 at $54.1 million [26] Business Line Data and Key Metrics Changes - Radiopharmaceutical oncology, solely comprised of PYLARIFY, generated Q4 revenue of $240.2 million, down 9.7% year-over-year, and full-year revenue of $989.1 million, down 6.5% [21] - Precision Diagnostics delivered Q4 revenue of $143.2 million, a 22% increase, driven by DEFINITY and Neuraceq, which contributed $31 million in Q4 [22][14] - Strategic partnerships and other revenue was $23.3 million, up 203.3%, due to strong performance from MK-6240 [22] Market Data and Key Metrics Changes - PYLARIFY volume increased approximately 4% year-over-year, with pricing concessions resetting 340B pricing in Q4 2025 [12] - Neuraceq is positioned as the second-most utilized and fastest-growing beta-amyloid PET imaging agent, addressing a large and expanding market [15] - DEFINITY maintained over 80% market share, delivering over $85 million in Q4 [15] Company Strategy and Development Direction - The company is focusing on radiodiagnostics, having divested its legacy SPECT business to prioritize innovative PET radiodiagnostics [8] - The strategy includes maintaining leadership in PSMA PET imaging with PYLARIFY and preparing for the launch of a new PSMA PET formulation in Q4 2026 [8][36] - The company plans to maximize the value of its current product portfolio while selectively developing pipeline assets and optimizing the therapeutic pipeline [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive meaningful performance gains and deliver sustainable revenue growth in the mid and long term [11] - The focus for 2026 will be on commercial execution and regulatory milestones, with expectations for multiple FDA approvals [9][11] - Management highlighted the importance of maintaining operational excellence and customer relationships to support growth [12] Other Important Information - The company repurchased $100 million of its own shares during Q4, leaving $200 million of authorization for buybacks outstanding [28] - The effective tax rate was 19% for Q4 and 25.3% for the full year [26] - The company anticipates a revenue forecast of $1.4 billion to $1.45 billion for 2026, with PYLARIFY expected to decline 8%-10% year-over-year [31] Q&A Session Summary Question: What will be the timing for securing coding and reimbursement for the new PSMA PET imaging agent? - Management anticipates securing HCPCS code and transitional pass-through status by October 1st, with a commercial rollout planned for Q4 2026 [42][43] Question: How does the study comparing PYLARIFY and POSLUMA impact the forecast? - Management expressed concerns about the study design and stated that the results do not impact their forecast [46][49] Question: Can you elaborate on pricing and unit growth in Q4 2025? - Management noted a strong quarter for PYLARIFY, with volume growth of 4% and a favorable pricing environment [51][52] Question: What are the plans for radiotherapeutic assets? - The company is reviewing its therapeutic assets and considering value-maximizing alternatives while focusing on diagnostic assets [60][62] Question: What is the growth potential for Neuraceq? - Management expects triple-digit growth for Neuraceq, driven by expanding manufacturing and deeper penetration in existing accounts [66][68]

Core Insights - Lantheus Holdings, Inc. reported strong financial results for Q4 and full year 2025, maintaining market leadership with PYLARIFY and expanding its portfolio through acquisitions [2][3][6] Financial Performance - Worldwide revenue for Q4 2025 was $406.8 million, a 4.0% increase from $391.1 million in Q4 2024 [3][7] - GAAP net income for Q4 2025 was $54.1 million, compared to a loss of $11.8 million in Q4 2024, marking a 558.8% improvement [3][7] - Adjusted net income for Q4 2025 was $110.7 million, slightly down by 4.1% from $115.4 million in Q4 2024 [3][7] - Fully diluted earnings per share (EPS) increased to $0.82 in Q4 2025 from a loss of $0.17 in Q4 2024, a 578.8% increase [3][7] Revenue Breakdown - Sales of PYLARIFY decreased by 9.7% to $240.2 million in Q4 2025 [7][21] - DEFINITY sales were $85.3 million, down 1.0% [7][21] - Neuraceq generated $31.0 million in sales, marking a 100% increase as it was newly introduced [7][21] Strategic Focus - The company is sharpening its strategic focus on PET radiodiagnostics and plans to pursue value-maximizing alternatives for its radiotherapeutic assets [2][6][15] - Lantheus aims for up to four FDA approvals in 2026 and is prioritizing execution and investment in its late-stage pipeline [2][6] Guidance for 2026 - The company provided revenue guidance for FY 2026 in the range of $1.4 billion to $1.45 billion and adjusted fully diluted EPS guidance of $5.00 to $5.25 [10]

Core Viewpoint - Lantheus Holdings, Inc. is a leading company in the radiopharmaceutical sector, focused on improving patient outcomes through innovative solutions [1][3]. Company Overview - Lantheus has been providing radiopharmaceutical solutions for 70 years and is headquartered in Massachusetts, with additional offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom [3]. - The company is dedicated to helping clinicians Find, Fight, and Follow disease [1][3]. Upcoming Events - Mary Anne Heino, Executive Chairperson and CEO, will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 11:10 a.m. ET [4]. - The company will also participate in the Leerink Global Healthcare Conference on March 10, 2026, at 8:00 a.m. ET [4]. Investor Relations - Live webcasts of the presentations will be accessible on the company's website, with replays available for at least 30 days following the live events [2].

Core Viewpoint - Perspective Therapeutics, Inc. has announced an underwritten offering of common stock and pre-funded warrants, aiming to raise approximately $175 million to support its clinical development and operational needs [1][3]. Group 1: Offering Details - The company is offering 39,576,088 shares of common stock at $3.79 per share and pre-funded warrants for 6,598,046 shares at $3.789 each, with gross proceeds expected to be around $175 million before expenses [1]. - The offering is set to close on or about February 3, 2026, pending customary closing conditions [1]. Group 2: Investor Participation - Notable investors in the financing include Commodore Capital, TCGX, Spruce Street Capital, Surveyor Capital, Affinity Asset Advisors, HBM Healthcare Investments, and Ally Bridge Group [2]. Group 3: Use of Proceeds - The net proceeds from the offering will be utilized for advancing clinical development, investing in manufacturing facilities, and general corporate purposes, with potential for acquiring complementary products or technologies [3]. Group 4: Company Overview - Perspective Therapeutics is focused on developing advanced radiopharmaceutical treatments for cancer, utilizing proprietary technology that targets cancer cells with alpha-emitting isotopes [7]. - The company is also working on complementary imaging diagnostics to enhance treatment personalization and efficacy [7]. - Current clinical programs include neuroendocrine tumors, melanoma, and solid tumors, which are in Phase 1/2a trials in the U.S. [8].

Core Insights - Telix Pharmaceuticals reported fiscal 2025 revenue of approximately $804 million, meeting its upgraded guidance of $800-$820 million [1] - The company experienced a significant 46% year-over-year increase in fourth quarter revenue, totaling around $208 million [2] - The Precision Medicine business generated approximately $161 million in revenue, reflecting a 4% quarter-over-quarter growth driven by the successful U.S. launch of Gozellix [2] Financial Performance - Fiscal 2025 revenue was approximately $804 million, aligning with guidance [1] - Fourth quarter revenue increased by 46% year-over-year to around $208 million [2] - Precision Medicine revenue was approximately $161 million, with a 4% quarter-over-quarter growth [2] Clinical Advancements - The company is advancing clinical studies, including the ProstACT Global Phase 3 study and the SOLACE Phase 1 study in the U.S. [3] - Telix dosed the first patient in the U.S. for the BiPASS Phase 3 trial to evaluate its PSMA-PET imaging agents [4] Strategic Collaborations - Telix announced a strategic collaboration with Varian to explore the combination of its radiopharmaceuticals with external beam radiation therapy [5] Stock Performance - Telix stock is currently trading 5.5% below its 20-day simple moving average and 22.6% below its 100-day SMA, indicating a bearish trend [6] - Over the past 12 months, shares have decreased by 56.91% [6] - The stock carries a Buy Rating with an average price target of $21.20, despite trading at a premium P/E multiple [8] Analyst Insights - Analysts view the shift from a diagnostic-focused business to a pure-play radiopharmaceutical company as a positive development [9] - The bull case for Telix is based on the potential for durable cash flows from Illuccix and Gozellix [9] Market Position - Telix Pharmaceuticals' Benzinga Edge scorecard indicates a challenging outlook, with low momentum and a premium value score [10] - The stock was down 6.86% at $7.20 at the time of publication [11]

Summary of Radiopharm Theranostics Conference Call Company Overview - **Company Name**: Radiopharm Theranostics - **Stock Symbols**: NASDAQ: RADX, ASX: RAD - **Industry**: Clinical stage radiotherapeutics - **Focus**: Development of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical needs [2][3] Core Business and Partnerships - **Core Business**: Radiopharmaceuticals, with a focus on first-in-class products [3] - **Strategic Partnerships**: - **Lantheus**: Largest shareholder with approximately 15% ownership [3] - **MD Anderson Cancer Center**: Scientific partnership for research and development [3] Pipeline and Clinical Trials - **Clinical Stage Molecules**: Five molecules currently in clinical stage [3] - **Key Products**: - **RAD101**: Imaging agent for brain metastasis, currently in Phase II with over 50% trial recruitment [4][6] - **PD-L1 Nanobody**: In Phase I, targeting multiple solid tumors [10] - **HER2 Nanobody**: In Phase I, targeting breast and gastroesophageal cancer [10] - **RV01**: Monoclonal antibody targeting B7-H3, expected to dose first patient in February [5] - **KLK3-targeting Monoclonal Antibody**: Radiolabeled with Terbium-161, also expected to dose first patient soon [5] Clinical Milestones and Data - **Upcoming Milestones**: - Completion of Phase II enrollment for RAD101 expected by March or April 2026 [14] - Full data release for Phase II anticipated before June 2026 [14] - Significant clinical data for RAD204 and RAD102 expected mid-2026 [14] - **Interim Data**: Positive interim results for RAD101, with 92% of patients achieving primary endpoint [7][8] Market Position and Competition - **Competitive Advantage**: No other radiopharmaceuticals in development for brain metastasis imaging, positioning RAD101 as a first-in-class product [16] - **Comparison with Competitors**: - **Novartis**: Established leader with commercial products but focused on different therapeutic areas [24] - **Telix**: More focused on imaging rather than therapeutics [24] - **Point Biopharma**: Acquired by Lilly, with no direct competition to Radiopharm's pipeline [25] Financial Overview - **Burn Rate**: Approximately $6 million to $7 million per quarter, with sufficient cash to reach Q1 2027 [19] - **Revenue Generation Potential**: RAD101 is closest to commercialization, with potential market launch by 2029 [21] Supply Chain and Manufacturing - **Isotope Supply Chain**: Multiple suppliers secured for Lutetium-177 to ensure reliable supply [18] Strategic Vision - **Partnership Strategy**: Focus on clinical development with openness to partnerships or licensing as trials progress [27] - **Long-term Goals**: Aim to deliver clinical data in 2026 that supports future financing needs [19][29] Conclusion - **Outlook**: 2026 is expected to be a pivotal year for Radiopharm Theranostics, with a strong focus on execution and addressing unmet medical needs in cancer treatment [29]

Core Viewpoint - Lantheus Holdings, Inc. has completed the sale of its SPECT business to SHINE Technologies, allowing the company to focus on its growing portfolio of PET radiodiagnostics and microbubbles while advancing its pipeline of radiopharmaceuticals [1][2]. Company Overview - Lantheus is a leading radiopharmaceutical-focused company dedicated to improving patient outcomes through innovative diagnostic solutions [29]. - The company has been providing radiopharmaceutical solutions for 70 years and is headquartered in Massachusetts, with additional offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom [29]. Transaction Details - The sale includes Lantheus' SPECT business, diagnostic agents such as TechneLite, NEUROLITE, Xenon Xe-133 Gas, and Cardiolite, as well as the manufacturing facility in North Billerica, Massachusetts, and related Canadian operations [1]. - Solomon Partners Securities, LLC acted as the financial advisor for Lantheus during this transaction, with Foley Hoag LLP and Ropes & Gray LLP serving as legal advisors, and Ernst & Young LLP providing financial and tax advisory services [3]. SHINE Technologies Overview - SHINE Technologies, LLC is an industry leader in next-generation fusion technology, focusing on safety, cost-efficiency, and environmental responsibility [30]. - The company has successfully commercialized fusion technology across various applications, including medical isotope production essential for diagnosing heart disease and cancer [31]. - SHINE is also pioneering nuclear waste recycling to enhance the sustainability of nuclear energy and aims to change energy production through commercializing fusion energy [32].